News headlines about OncoCyte Corp (NYSE:OCX) have been trending positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OncoCyte Corp earned a news sentiment score of 0.34 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.203122812193 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Separately, Zacks Investment Research upgraded shares of OncoCyte Corp from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th.
OncoCyte Corp (NYSE:OCX) last posted its quarterly earnings results on Monday, August 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01).
About OncoCyte Corp
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.